Amaria, R., Prieto, P., Tetzlaff, M., Reuben, A., Andrews, M., Ross, M., … Wargo, J. (2018). Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 19(2), 181-193. https://doi.org/10.1016/S1470-2045(18)30015-9

, Spencer, C., Nezi, L., Reuben, A., Andrews, M., Karpinets, T., … Wargo, J. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.), 359(6371), 97-103. https://doi.org/10.1126/science.aan4236 (Original work published 2018)

Reuben, A., Spencer, C., Prieto, P., , Reddy, S., Miller, J., … Wargo, J. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genomic Medicine, 2. https://doi.org/10.1038/s41525-017-0013-8 (Original work published 2017)

Roh, W., Chen, P., Reuben, A., Spencer, C., Prieto, P., Miller, J., … Futreal, P. (2017). Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 9(379). https://doi.org/10.1126/scitranslmed.aah3560 (Original work published 2017)